Quantcast
Home > Quotes > RTTR

Ritter Pharmaceuticals, Inc. Common Stock (RTTR) Quote & Summary Data

RTTR 
$0.9103
*  
0.013
1.41%
Get RTTR Alerts
*Delayed - data as of Jun. 24, 2019  -  Find a broker to begin trading RTTR now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    RTTR Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
6
Today's High / Low
$ 0.9419 / $ 0.90
Share Volume
43,385
50 Day Avg. Daily Volume
369,955
Previous Close
$ 0.9233
52 Week High / Low
$ 2.91 / $ 0.47
Market Cap
8,231,233
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.62

Intraday Chart

Shares Traded

Share Volume:
43,385
50 Day Avg. Daily Volume:
369,955

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.81

Trading Range

The current last sale of $0.9103 is 93.68% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.9419 $ 2.91
 Low: $ 0.90 $ 0.47

Company Description (as filed with the SEC)

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the gut microbiome to treat digestive disorders and gastrointestinal diseases. Our lead product candidate, RP-G28, is an orally administered, high purity galacto-oligosaccharide ("GOS"), currently in Phase 3 clinical development for the treatment of lactose intolerance ("LI"), a condition that affects millions of people worldwide. RP-G28 is designed to selectively stimulate the growth of lactose-metabolizing bacteria in the colon, thereby effectively adapting the gut microbiome to assist in digesting lactose (the sugar found in milk) that reaches the large intestine. RP-G28 has the potential to become the first drug approved by the Food and Drug Administration ("FDA") for the treatment of LI.  ... More ...  



Risk Grade

Where does RTTR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.9055
Open Date:
Jun. 24, 2019
Close Price:
$ 0.9103
Close Date:
Jun. 24, 2019


Consensus Recommendation

Analyst Info